 |
December 2007 |
| |
12/11/2007
Immunovative Therapies announced today that a scientific paper regarding the novel “Mirror Effect” anti-tumor mechanism has been published online ahead of print in the peer-reviewed journal entitled Medical Hypotheses. The “Mirror Effect” is a theory developed to design treatments to harness the curative immune effect that occurs in allogeneic Bone Marrow/Stem Cell transplant procedures (BMT) without the need for a matched donor and without the severe and often lethal toxicity associated with BMT. This is the medical theory which supports the development of AlloStim™, which is awaiting final regulatory approval for first human clinical trials to begin at Hadassah Medical Center in Jerusalem. The online paper can be viewed here. |
| |
|
|
November 2007 |
| |
11/11/2007
Immunovative announces today that it has received approval from the Hadassah Medical Center Helsinki Committee to initiate a Phase I human clinical trial of AlloStim™ in advanced hematological malignancy. Prior to initiating the clinical trial, approval must also be obtained from the Israel Ministry of Health.
|
|
October 2007 |
| |
10/30/2007
Immunovative Therapies announced today that it has entered into a contract with Hadasit to conduct Phase I/II human clinical trials of its AlloStim product at Hadassah-Hebrew University Medical Center in Jerusalem. The trial will begin upon obtaining all the required regulatory approvals.
|
| |
|
|
August 2007 |
| |
8/30/2007
Immunovative announced today that it has closed its current $0.50 per share private placement , having raised a total of $1,046,000. These funds will support the completion of Phase I/II clinical trials.
07/30/2007 (10:08 A.M.)
Immunovative announced today that it has entered into an exclusive license for a therapeutic cancer vaccine based on heat shock proteins with the University of Arizona. The Company plans to initially combine this technology with its AlloStim™ product candidate as a maintenance therapy for hematological malignancies after chemotherapy induction therapy. |
| |
|
|
July 2007 |
| |
07/08/2007
Immunovative scientists working in collaboration with Ichilov Hospital announced today preliminary results of research experiments with the Company’s experimental drug candidate, AlloStim™. One of the problems scientists have encountered in trying to develop immunotherapy-based dendritic cell vaccines has been the difficulty in causing human dendritic cells to mature and produce the cytokine IL-12. It has been shown that dendritic cells which produce IL-12 are superior in terms of their ability to promote anti-tumor immunity. Our scientist now have data which demonstrates that AlloStim™ can induce human dendritic cells to mature and produce IL-12. These data provide support for the strong adjuvant effect AlloStim™ can have when combined with tumor vaccination protocols. Based on these findings, the Company is seeking to in-license vaccine technology for use in combination with AlloStim™.
07/08/2007 (7:32 P.M.)
Newsletter available for shareholders which provides an update on our progress toward human clinical trials. Any shareholders that have not yet seen this important status update can request a copy by email: info@immunovative.co.il |
| |
|
|
June 2007 |
| |
06/14/2007
The immune effect that occurs in Allogeneic bone marrow transplant procedures is proven to cure patients with bulky tumors resistant to chemotherapy and radiation, but also results in lethal GVHD toxicity. AlloStim retains the proven effectiveness of this immune response against cancer and eliminates GVHD toxicity. Click here to learn how it works |
|
|
| |
6/02/2007
Immunovative scientists at Hadassah Medical Center (Jerusalem) and Ichilov Hospital (Tel Aviv) announced today a significant research finding. One of the causes of Chronic Lymphocytic Leukemia (CLL) is that normal B cells lose the ability to undergo natural cell death (apoptosis) and thus grow continuously as tumors. Immunovative scientists have discovered that the cytokines produced by AlloStim are capable of making CLL cells susceptible to natural cell death and a molecule expressed on the surface of AlloStim™ (FasL) has a direct anti-tumor killing effect on CLL tumors. This is a significant new finding that holds potential for AlloStim not only to stimulate a patient-mediated anti-tumor immune response, but also may provide a direct and immediate effect on reducing tumor burden. |
| |
|
|
February 2007 |
| |
2/16/2007
Immunovative Therapies announced today that the Misgav Technology Center (MTC) Incubator management selected Immunovative as the best incubator
project of 2006. MTC also nominated Immunovative to be recognized by the
Office of the Chief Scientist as the outstanding incubator project of the
year for all of Israel.
|
| |
|
| |
2/06/2007
Immunovative Therapies announced today that its technology has been designated as "breakthrough technology" and has been selected to give an oral presentation at Israel Innovation Summit, March 21-22 in Haifa Israel. The Innovation Summit is an international gathering of academia, global corporations and emerging companies where Israeli breakthrough technology is introduced and discussed by top experts. http://www.israelinnovationsummit.com/reg1.com |
|
January 2007
|
| |
1/01/2007
Immunovative Therapies, Ltd. has announced today that it has successfully developed a process for producing consistent batches of AlloStim™ from normal blood donors. This is a significant milestone in the current development effects focused on completing the Chemistry, Manufacturing and Control section of a Investigational New Drug (IND) application under preparation. |
| |
|
More News..
|